Chemoinformaics analysis of N-[2-(4-Hydroxyphenyl)ethyl]benzamide
| Molecular Weight | 241.29 | nRot | 4 |
| Heavy Atom Molecular Weight | 226.17 | nRig | 22 |
| Exact Molecular Weight | 241.11 | nRing | 2 |
| Solubility: LogS | -4.142 | nHRing | 0 |
| Solubility: LogP | 4.065 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 2 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 33 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 18 | No. of Aromatic Carbocycles | 2 |
| nHetero | 3 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 15 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 12 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 12 |
| nHA | 2 | APOL | 37.7559 |
| nHD | 2 | BPOL | 16.4861 |
| QED | 0.646 |
| Synth | 2.738 |
| Natural Product Likeliness | 1.9 |
| NR-PPAR-gamma | 0.955 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.011 |
| Pgp-sub | 0.002 |
| HIA | 0.057 |
| CACO-2 | -4.668 |
| MDCK | 0.0000226 |
| BBB | 0.249 |
| PPB | 0.981568 |
| VDSS | 0.486 |
| FU | 0.0102558 |
| CYP1A2-inh | 0.972 |
| CYP1A2-sub | 0.79 |
| CYP2c19-inh | 0.875 |
| CYP2c19-sub | 0.355 |
| CYP2c9-inh | 0.857 |
| CYP2c9-sub | 0.935 |
| CYP2d6-inh | 0.888 |
| CYP2d6-sub | 0.756 |
| CYP3a4-inh | 0.668 |
| CYP3a4-sub | 0.223 |
| CL | 2.308 |
| T12 | 0.176 |
| hERG | 0.047 |
| Ames | 0.886 |
| ROA | 0.842 |
| SkinSen | 0.511 |
| Carcinogencity | 0.952 |
| EI | 0.903 |
| Respiratory | 0.908 |
| NR-Aromatase | 0.717 |
| Antiviral | No |
| Prediction | 0.701962 |